Benson et al., 2014 - Google Patents
Colon cancer, version 3.2014Benson et al., 2014
- Document ID
- 2929483218949482114
- Author
- Benson A
- Venook A
- Bekaii-Saab T
- Chan E
- Chen Y
- Cooper H
- Engstrom P
- Enzinger P
- Fenton M
- Fuchs C
- Grem J
- Hunt S
- Kamel A
- Leong L
- Lin E
- Messersmith W
- Mulcahy M
- Murphy J
- Nurkin S
- Rohren E
- Ryan D
- Saltz L
- Sharma S
- Shibata D
- Skibber J
- Sofocleous C
- Stoffel E
- Stotsky-Himelfarb E
- Willett C
- Gregory K
- Freedman-Cass D
- Publication year
- Publication venue
- Journal of the National Comprehensive Cancer Network
External Links
Snippet
The NCCN Guidelines for Colon Cancer address diagnosis, pathologic staging, surgical management, perioperative treatment, posttreatment surveillance, management of recurrent and metastatic disease, and survivorship. This portion of the guidelines focuses on the use …
- 206010009944 Colon cancer 0 title abstract description 24
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
- C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Benson et al. | Colon cancer, version 3.2014 | |
Benson et al. | Colon cancer, version 1.2017, NCCN clinical practice guidelines in oncology | |
Benson et al. | Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology | |
Benson et al. | Colon cancer | |
Maron et al. | Targeted therapies for targeted populations: anti-EGFR treatment for EGFR-amplified gastroesophageal adenocarcinoma | |
Petrylak et al. | Safety and clinical activity of atezolizumab in patients with metastatic castration-resistant prostate cancer: a phase I study | |
Collins et al. | Product review: avelumab, an anti-PD-L1 antibody | |
Dienstmann et al. | Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials | |
Ricciardi et al. | NSCLC and HER2: between lights and shadows | |
Battaglin et al. | The role of tumor angiogenesis as a therapeutic target in colorectal cancer | |
Lombardi et al. | Adjuvant colon cancer chemotherapy: where we are and where we'll go | |
Martini et al. | Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: what does still need to be addressed? | |
Lorch et al. | Identification of recurrent activating HER2 mutations in primary canine pulmonary adenocarcinoma | |
JP2016105096A (en) | Biomarkers and methods of treatment | |
CN102216331A (en) | Treatment method | |
Benson et al. | Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology | |
Burgenske et al. | Establishment of genetically diverse patient-derived xenografts of colorectal cancer | |
De Mattos-Arruda et al. | Development of molecular biomarkers in individualized treatment of colorectal cancer | |
JP2017516458A (en) | Cancer treatment with c-met antagonist and correlation with HGF expression of c-met antagonist | |
Ruiz-Banobre et al. | Predictive biomarkers in metastatic colorectal cancer: A systematic review | |
Ha et al. | Phase II trial of cetuximab in patients with metastatic or locally advanced soft tissue or bone sarcoma | |
Smithy et al. | Pancreas cancer: therapeutic trials in metastatic disease | |
Cheetham et al. | New agents for the treatment of advanced bladder cancer | |
Zhang et al. | Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study) | |
Taieb et al. | Treatment of gastric adenocarcinoma: A rapidly evolving landscape |